Domov › Množni mielom › North Carolina › Durham
Klinične študije za Množni mielom v Durham, NC
37 študij za Množni mielom išče udeležence na lokacijah v Durham in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Vključevanje udeležencevFaza 3
- Research Site, Chapel Hill · 10 mi stran
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Vključevanje udeležencevFaza 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi stran
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Vključevanje udeležencevFaza 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi stran
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Vključevanje udeležencevFaza 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi stran
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Vključevanje udeležencevFaza 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi stran
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Vključevanje udeležencevFaza 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi stran
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Vključevanje udeležencevFaza 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi stran
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Vključevanje udeležencevFaza 1/2
- GSK Investigational Site, Chapel Hill · 10 mi stran
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Vključevanje udeležencevFaza 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Vključevanje udeležencevFaza 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi stran
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Vključevanje udeležencev
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi stran
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Vključevanje udeležencevFaza 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi stran
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Vključevanje udeležencevFaza 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi stran
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Vključevanje udeležencevFaza 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi stran
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Vključevanje udeležencevFaza 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi stran
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Vključevanje udeležencevFaza 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi stran
Registry of Older Patients With Cancer
Vključevanje udeležencevOpazovalna študija
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi stran
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Vključevanje udeležencevFaza 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Vključevanje udeležencevFaza 2
- University of North Carolina, Chapel Hill · 10 mi stran
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi stran
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi stran
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Vključevanje udeležencevFaza 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi stran
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Vključevanje udeležencevFaza 1
- University of North Carolina, Chapel Hill · 10 mi stran
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Vključevanje udeležencevFaza 1
- University of North Carolina, Chapel Hill · 10 mi stran
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Vključevanje udeležencevFaza 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi stran
Registry for Adults With Plasma Cell Disorders (PCD's)
Vključevanje udeležencevOpazovalna študija
- North Carolina Cancer Hospital, Chapel Hill · 10 mi stran
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Vključevanje udeležencevOpazovalna študija
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi stran
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Duke University Health System (DUHS), Durham
Študije za Množni mielom v drugih mestih
- New York City, NY60 študij
- Boston, MA42 študij
- Atlanta, GA41 študij
- Houston, TX38 študij
- Nashville, TN32 študij
- Denver, CO27 študij
- Rochester, MN24 študij
- St. Louis, MO24 študij
- Columbus, OH24 študij
- Baldwin Park, CA23 študij
- Chicago, IL22 študij
- Seattle, WA22 študij
Druge študije v Durham
- Rak dojke63 študij
- Rak (vse vrste)58 študij
- Nemalicelični pljučni rak39 študij
- Metastatski rak33 študij
- Akutna mieločna levkemija33 študij
- Rak pljuč32 študij
- Rak prostate32 študij
- Kolorektalni rak28 študij
- Kronična limfocitna levkemija27 študij
- Rak jajčnikov27 študij
- Srčno popuščanje26 študij
- Rak trebušne slinavke24 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.